Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04509193 · ClinicalTrials.gov registry record
A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 116,049
- Enrollment target
NCT04509193: Completed study, sponsored by Bayer.
NCT04509193 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 116,049 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04509193 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 116,049 participants
- Enrollment target
Study Summary
In people with type 2 diabetes, the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels. People with diabetes are more likely to have non-valvular atrial fibrillation (NVAF) compared to people who do not have diabetes. Having both NVAF and diabetes can increase the chances of developing other serious health conditions, like blood clots and strokes. People with NVAF may receive treatments to help lower the risk of blood clots. This can then help to lower the risk of having a stroke. Two of these treatments are rivaroxaban and warfarin. In this study, the researchers will look at how well rivaroxaban works and how safe it is compared to warfarin in routine clinical practice. The study will include men and women who are at least age 18 and who have NVAF and type 2 diabetes. The researchers in this study will use the participants' health information from an electronic database.
Interventions
- DRUG Warfarin
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116,049 participants |
| Start Date | 2020-08-21 |
| Est. Completion | 2021-07-31 |
What the finished NCT04509193 record still lists
NCT04509193 is an observational study that tracks outcomes without assigning an intervention. Its 116,049 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT04509193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04509193 about?
NCT04509193 is a clinical study titled "A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes". In people with type 2 diabetes, the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels. People with diabetes are more likely to have non-valvular atrial fibrillation (NVAF) compared to people who do not have diabetes. Having b...
What is the current status of trial NCT04509193?
This trial is currently completed. The enrollment target is 116,049 participants. The study started on 2020-08-21. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04509193?
The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (Xarelto, BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT04509193?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06251323 · 119,680 participants · NA
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
- NCT03897374 · 120,000 participants
Strategic Targeting for Optimal Prevention of Cancer
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
- NCT05804188 · 105,000 participants
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI